Canadian healthcare company Nuvo Pharmaceuticals Inc (TSX:NRI) (OTCQX:NRIFF) said on Wednesday that Dr. Reddy's Laboratories Inc (DRL) has launched its generic version of Vimovo in the United States.
The market launch of DRL's generic version of Vimovo is reportedly "at risk" as Nuvo Pharmaceuticals (Ireland) DAC (Nuvo Ireland) continues to hold valid US Patent Nos. 8,858,996 and 9,161,920 (the '996 and '920 patents) covering Vimovo in the US market.
Currently, the '996 and '920 patents are the subject of patent infringement litigation against DRL. The companies have mutually agreed on a pretrial litigation schedule with the court extending through to mid-2021. The term of the '996 and '920 patents extends to 31 May 2022.
Following the launch of the generic version of Vimovo in the US, Nuvo Ireland's USD7.5m annual minimum royalty from its partner has ceased. However, the launch of generic Vimovo in the US does not impact Nuvo Ireland's global Vimovo business in markets outside of the US. Nuvo Ireland will continue to receive royalty payments from its global partner, Grunenthal GmbH, on global net sales of Vimovo.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical